Zytiga
/
Zytiga (abiraterone) is an androgen biosynthesis inhibitor used to treat metastatic castration-resistant prostate cancer. It is given as an oral tablet and is available only by prescription. Patients should know that Zytiga may cause liver problems and should not be used in those with severe liver impairment. Also, blood pressure monitoring is necessary, as Zytiga can cause hypertension.
Interactions
Ketoconazole: May increase abiraterone plasma concentrations, potentially leading to increased risk of adverse effects. Monitor for increased side effects and consider dose adjustments.
Rifampin: Can significantly decrease abiraterone plasma concentrations, which may reduce its effectiveness. Avoid concomitant use.
Warfarin: Abiraterone may affect the anticoagulant effect of warfarin. Monitor INR closely and adjust warfarin dose as necessary.
Food (high-fat meals): Increases the absorption of abiraterone, which may lead to higher plasma concentrations. Administer abiraterone on an empty stomach (at least 1 hour before or 2 hours after a meal).
25
commonly-prescribed
medication.